title: Longitudinal BNP follow-up as a marker of treatment response in acute heart failure: Relationship with objective markers of decongestion.
abstract: BACKGROUND
  Results of studies that examined the value of B-type natriuretic peptide (BNP) reduction as a marker of decongestion have been inconsistent. We investigated whether longitudinal admission-to-discharge BNP reduction can be used to monitor decongestion during acute heart failure (HF).
  
  
  METHODS
  We used the ESCAPE trial data to study the relationship between the magnitude of BNP reduction and various clinical and objective markers of decongestion.
  
  
  RESULTS
  Admission-to-discharge reduction in BNP was recorded in 245 patients who were divided into tertiles (tertile 1 had BNP reduction<27pg/mL, tertile 2 had BNP reduction 27-334pg/mL and tertile 3 had BNP reduction>334pg/mL). There were significant differences across tertiles with regard to resolution of jugular venous distension (JVD, P=0.014) and orthopnea (P=0.04) on discharge, admission-to-discharge weight loss (P=0.002), and admission-to-discharge reduction in inferior vena cava (IVC) diameter (P=0.0001). Compared with the first tertile, patients in the third tertile had significantly higher frequency of resolution of JVD (univariate OR 2.657, P=0.004) and orthopnea (univariate OR 2.083, P=0.032) on discharge, more weight loss (P=0.001), higher IVC diameter reduction (P<0.0001), and higher reduction in pulmonary capillary wedge pressure (PCWP) from admission to day of PAC removal compared with first tertile (P<0.0001). Using the whole cohort, we found a significant correlation between admission-to-discharge BNP reduction and admission-to-discharge weight loss (n=232, r=0.211, P=0.001), admission-to-discharge reduction in IVC diameter (n=99, r=0.360, P<0.0001) and reduction in PCWP from admission to the day of pulmonary artery catheter removal (n=92, r=0.242, P=0.02).
  
  
  CONCLUSIONS
  Admission-to-discharge BNP reduction is a reasonable marker of treatment response in HF that correlated with clinical and objective markers of decongestion.
authors.affiliation: Internal Medicine Department, Mercy Medical Center, Clinton, IA, USA. Electronic address: hesham.omar@apogeephysicians.com.
authors.forename: Hesham R
authors.initials: HR
authors.lastname: Omar
authors.affiliation: Division of Cardiovascular Medicine, Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, KY, USA.
authors.forename: Maya
authors.initials: M
authors.lastname: Guglin
mesh_terms: D000208:Acute Disease; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D002407:Catheterization, Swan-Ganz / Q000379:methods*; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods*; D020097:Natriuretic Peptide, Brain / Q000032:analysis / Q000097:blood; D010043:Outcome and Process Assessment, Health Care; D010346:Patient Care Management / Q000379:methods; D010351:Patient Discharge / Q000706:statistics & numerical data; D010359:Patient Readmission / Q000706:statistics & numerical data; D010446:Peptide Fragments / Q000032:analysis / Q000097:blood; D011669:Pulmonary Wedge Pressure; D014682:Vena Cava, Inferior / Q000000981:diagnostic imaging*
chemical_list: D015415:Biomarkers; D010446:Peptide Fragments; D020097:Natriuretic Peptide, Brain
keywords: B-type natriuretic peptide; Decongestion; Heart failure; IVC diameter